2014 EASO Position Statement on the Use of Anti-Obesity Drugs

Obesity Facts

Volumn 8, Issue 3, 2015, Pages 166-174

  Toplak, Hermann ^a   Woodward, Euan ^b   Yumuk, Volkan ^c   Oppert, Jean Michel ^d   Halford, Jason C G ^e   Frühbeck, Gema ^f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b European Association for the Study of Obesity (EASO)   (United Kingdom)

^c ISTANBUL UNIVERSITY   (Turkey)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; LIRAGLUTIDE; LORCASERIN; NALTREXONE; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ARTICLE; BARIATRIC SURGERY; BODY WEIGHT; BODY WEIGHT MANAGEMENT; COMORBIDITY; DIET SUPPLEMENTATION; DRUG USE; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; OBESITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; WEIGHT REDUCTION; EUROPE; MEDICAL SOCIETY;

ANTI-OBESITY AGENTS; EUROPE; HUMANS; OBESITY; SOCIETIES, MEDICAL;

EID: 84929698525     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000430801     Document Type: Article

References (38)

1. Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM: Obesity: the gateway to ill health-an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts 2013; 6: 117-120.
2. World Health Organisation: Fact Sheet No.311 (May 2012). www.who.int./mediacentre/factsheets/fs311/en/.
3. Frühbeck G: Obesity: screening for the evident in obesity. Nat Rev Endocrinol 2012: 8:570-572.
4. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, Baugh V, Bekedam H, Billo N, Casswell S, Cecchini M, Colagiuri S, Collins T, Ebrahim S, Engelgau M, Galea G, Gaziano T, Geneau R, Haines A, Hospedales J, Jha P, Keeling A, Leeder S, Lincoln P, McKee M, Mackay J, Magnusson R, Moodie R, Mwatsama M, Nishtar S, Norrving B, Patterson D, Piot P, Ralston J, Rani M, Reddy KS, Sassi F, Sheron N, Stuckler D, Suh I, Torode J, Varghese C, Watt J; Lancet NCD Action Group; NCD Alliance: Priority actions for the non-communicable disease crisis. Lancet 2011; 377: 1438-1447.
5. Yumuk V, Frühbeck G, Oppert JM, Woodward E, Toplak H, for the Executive Committee of the European Association for the Study of Obesity: An EASO position statement on multidisciplinary obesity management in adults. Obes Facts 2014; 7: 96-101.
6. Tsigos C, Hainer V, Basdevant A, Finer N, Mathus-Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Yumuk V, Zahorska-Markiewicz B: Criteria for EASO-collaborating centres for obesity management. Obes Facts 2011; 4: 329-333.
7. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The Aace Obesity Scientific Committee: American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action. Endocr Pract 2014; 20: 956-976.
8. Maggio AB, Martin XE, Saunders Gasser C, Gal-Duding C, Beghetti M, Farpour-Lambert NJ, Chamay-Weber C: Medical and non-medical complications among children and adolescents with excessive body weight. BMC Pediatr 2014; 14: 232.
9. Blundell JE, Dulloo AG, Salvador J, Frühbeck G, on behalf of the EASO SAB Working Group on BMI: Beyond BMI-phenotyping the obesities. Obes Facts 2014; 7: 322-328.
10. Tsigos C, Hainer V, Basdevant A, Finer N, Fried M, Mathus-Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Zahorska-Markiewicz B: Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1: 106-116.
11. Hainer V, Toplak H, Mitrakou A: Treatment modalities of obesity: what fits whom? Diabetes Care 2008; 31(suppl 2):S269-S277.
12. Patrick DL, Skalicky AM, Edwards TC, Kuniyuki A, Morales LS, Leng M, Kirschenbaum DS: Weight loss and changes in generic and weight-specific quality of life in obese adolescents. Qual Life Res 2011; 20: 961-968.
13. Toplak H, Marhardt K: Reduction of obesity and improvement in metabolic parameters by inhibition of intestinal lipases: current results with orlistat. Acta Med Austriaca 1998; 25: 142-145.
14. Van Gaal LF, Broom JI, Enzi G, Toplak H: Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998; 54: 125-132.
15. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
16. Sharma AM, Golay A: Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20: 1873-1878.
17. Hutton B, Fergusson D: Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-1468.
18. George M, Rajaram M, Shanmugam E: New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther 2014; 19: 65-76.
19. Rodgers RJ, Tschop MH, Wilding JP: Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5: 621-626.
20. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C: The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577-1579.
21. Yanovski SZ, Yanovski JA: Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74-86.
22. Smith SR, O'Neil PM, Astrup A, Finer N, Sanchez-Kam M, Fraher K, Fain R, Shanahan WR: Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014; 22: 2137-2146.
23. Sweeting AN, Tabet E, Caterson ID, Markovic TP: Management of obesity and cardiometabolic risk-role of phentermine/extended release topiramate. Diabetes Metab Syndr Obes 2014; 7: 35-44.
24. Garvey WT: Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf 2013; 12: 741-756.
25. Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, Troupin B, Day WW: Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014; 37: 912-921.
26. Verpeut JL, Bello NT: Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 2014; 13: 831-841.
27. www.biotechnologyevents.com/node/7809.
28. Torekov SS, Madsbad S, Holst JJ. Obesity-an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011; 12: 593-601.
29. Iepsen EW, Torekov SS, Holst JJ: Therapies for inter-relating diabetes and obesity-GLP-1 and obesity. Expert Opin Pharmacother 2014; 15: 2487-2500.
30. Ng SY, Wilding JP: Liraglutide in the treatment of obesity. Expert Opin Biol Ther 2014; 14: 1215-1224.
31. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37: 1443-1451.
32. Bray GA: Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol 2014; 28: 665-684.
33. Manning S, Pucci A, Finer N: Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014; 5: 135-148.
34. Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, Sharma AM, Ge H, Santoro D, Shepherd G, James P; SCOUT Investigators: Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring) 2010; 18: 987-994.
35. Seimon RV, Espinoza D, Ivers L, Gebski V, Finer N, Legler UF, Sharma AM, James WP, Coutinho W, Caterson ID: Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. Int J Obes (Lond) 2014; 38: 1165-1171.
36. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP; SCOUT Investigators: Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530.
37. Fleming JW, McClendon KS, Riche DM: New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother 2013; 47: 1007-1016.
38. Cunningham JW, Wiviott SD: Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clin Cardiol 2014; 37: 693-699.